To confirm these effects in different ER+ breast cancer cells, we used ZR-75-1 cells for treatment with tamoxifen or 4-OHT and observed similar dose-dependent effects of both drugs on the induction of TARBP2 expression under short-term and noncytotoxic treatments (Figure 3C,D). Here, ESR1 is linked to breast carcinoma.